3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
36
Neoplasm Metastasis
12
Neoplasms
10
Colorectal Neoplasms
5
Thyroid Neoplasms
4
Thyroid Cancer, Papillary
4
Multiple Myeloma
4
Leukemia, Hairy Cell
4
Hematologic Neoplasms
4
Skin Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Thyroid Carcinoma, Anaplastic
2
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoma, Non-Hodgkin
2
Brain Neoplasms
2
Thyroid cancer, follicular
1
Thrombocytosis
1
Sarcoma, Clear Cell
1
Sarcoma
1
Relapsed Pediatric Solid Tumor
1
Rare Tumour
1
Rare Tumor
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Rituximab
5
fludarabine
4
Tacrolimus
4
Epoetin Alfa
4
Cyclophosphamide
4
Busulfan
4
Darbepoetin alfa
3
Alemtuzumab
3
fludarabine phosphate
2
entrectinib
2
atezolizumab
2
alectinib
2
Thiotepa
2
Therapeutics
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methotrexate
2
Etoposide
2
Early Intervention, Educational
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
trametinib
1
tirbanibulin
1
sargramostim
1
plerixafor
1
phenethyl isothiocyanate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoproliferative Disorders
×
Vemurafenib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled